Akèy › Kansè Ezofajyen › Virginia
Etid klinik pou Kansè Ezofajyen nan Virginia
16 etid pou Kansè Ezofajyen ap chèche patisipan nan sit nan Virginia.
Vil nan Virginia
Tèks ofisyèl etid la (Anglè)
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
- VCU Massey Comprehensive Cancer Center, Richmond
- VCU Community Memorial Health Center, South Hill
- VCU Health Tappahannock Hospital, Tappahannock
Ap rekriteVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07283939Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Chesapeake Regional Medical Center, Chesapeake
- Augusta Health Center for Cancer and Blood Disorders, Fishersville
- Bon Secours Memorial Regional Medical Center, Mechanicsville
- ak 7 plis
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT05334069A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
- Site 04, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07814248Phase 1 Study of PF-08046033 in Advanced Solid Tumors
- Inova Schar Cancer Infusion Pharmacy, Fairfax
- Inova Schar Cancer, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07519655Pan-tumor MRD Study
- Virginia Cancer Institute, Richmond
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06605404Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- NEXT Oncology Virginia, Fairfax
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06128551Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Virginia Cancer Specialists, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT05983432Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Virginia Cancer Specialists, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT06293898Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Blacksburg
- Research Site, Fairfax
- Research Site, Fort Belvoir
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07431281The Vanguard Study: Testing a New Way to Screen for Cancer
- Sentara Martha Jefferson Hospital, Charlottesville
- Inova Schar Cancer Institute, Fairfax
- Inova Fair Oaks Hospital, Fairfax
- ak 5 plis
Ap rekriteVolontè an sante akeyi
Laj 45 a 75 · Tout sèks · Mizajou Sep 2, 2026 · NCT06995898A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
- NEXT Virginia, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 27, 2026 · NCT07227168A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, Fairfax
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07749586A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Oncology & Hematology Associates of Southwest Virginia, Roanoke
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 29, 2026 · NCT03526835A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Virginia Cancer Specialists, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 6, 2026 · NCT04389632Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Virginia Cancer Specialists - Fairfax /ID# 232592, Fairfax
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 23, 2026 · NCT05005403SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Charlottesville
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.